Taiko Pharmaceutical Co., Ltd. AI Stock Analysis
Want to see JP:4574 full AI Analyst Report?
Taiko Pharmaceutical Co., Ltd. (4574) AI Stock Analysis
Taiko Pharmaceutical Co., Ltd.
(TSE/TYO:4574)
The score is driven primarily by improving fundamentals—renewed profitability, positive free cash flow, and significantly reduced leverage—tempered by a volatile multi-year earnings/cash-flow history. Technicals are largely neutral with the price still below the 200-day average, and valuation is fair (P/E ~19) with a modest dividend yield.
Taiko Pharmaceutical Co., Ltd. (4574) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 13.18B
- Dividend Yield
- 1.27%
- Average Volume (3M)
- 116.45K
- Price to Earnings (P/E)
- 19.0
- Beta (1Y)
- 0.62
- Revenue Growth
- 13.30%
- EPS Growth
- 66.38%
- Country
- Japan
- Employees
- 220
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Taiko Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A b...
Taiko Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Financials reflect a credible turnaround: profitability returned in 2024–2025 (net income ~¥0.9B) and debt fell sharply to ~¥0.82B (2025), improving balance-sheet risk. However, results have been volatile (large losses in 2021–2023) and cash-flow consistency is still being re-established despite positive 2024–2025 free cash flow (~¥0.52B in 2025).
Income Statement
57NeutralBalance Sheet
72PositiveCash Flow
54Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.62B | 6.40B | 6.29B | 6.12B | 5.04B | 10.72B |
| Gross Profit | 3.50B | 3.48B | 3.67B | 2.58B | 1.08B | 2.75B |
| EBITDA | 882.00M | 724.00M | 882.00M | -2.85B | -2.34B | -4.01B |
| Net Income | 688.00M | 923.00M | 898.00M | -3.61B | -4.89B | -9.59B |
Balance Sheet | ||||||
| Total Assets | 11.09B | 12.27B | 12.91B | 13.22B | 15.05B | 22.54B |
| Cash, Cash Equivalents and Short-Term Investments | 3.17B | 4.26B | 4.53B | 5.48B | 3.50B | 6.10B |
| Total Debt | 172.00M | 816.00M | 2.03B | 3.25B | 3.81B | 4.77B |
| Total Liabilities | 2.66B | 3.75B | 4.95B | 6.48B | 7.00B | 9.72B |
| Stockholders Equity | 8.43B | 8.52B | 7.96B | 6.74B | 8.04B | 12.81B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 523.00M | 205.00M | -421.00M | -2.08B | -3.19B |
| Operating Cash Flow | 0 | 814.00M | 362.00M | -307.00M | -1.99B | -1.59B |
| Investing Cash Flow | 0 | 142.00M | -5.00M | 1.17B | 190.00M | -1.62B |
| Financing Cash Flow | 0 | -1.23B | -1.18B | 1.54B | -997.00M | 3.96B |
Taiko Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4574, the sentiment is Negative. The current price of 259.00 is below the 20-day moving average (MA) of 261.05, above the 50-day MA of 258.50, and below the 200-day MA of 274.35, indicating a neutral trend. The MACD of 0.42 indicates Positive momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4574.
Taiko Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
JP:452481.5Outperform
JP:453864Neutral- JP:457460Neutral
JP:292957Neutral
JP:453946.5Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4524 | 82Outperform | JPY 8.92B | 11.51 | ― | 2.94% | -0.47% | 50.82% |
| JP:4538 | 64Neutral | JPY 18.70B | 8.35 | ― | 4.22% | 2.29% | ― |
| JP:4574 | 60Neutral | JPY 13.07B | 18.99 | ― | 1.27% | 13.30% | 66.38% |
| JP:2929 | 57Neutral | JPY 16.51B | 8.30 | ― | 3.88% | -3.12% | 406.78% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4539 | 47Neutral | JPY 5.31B | -11.17 | ― | 3.40% | 0.31% | -194.72% |
| JP:4512 | 45Neutral | JPY 9.96B | 28.80 | ― | 1.22% | 23.41% | 149.71% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 259.00 | -39.00 | -13.09% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 566.00 | -211.24 | -27.18% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 286.00 | 2.39 | 0.84% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2214.00 | 141.45 | 6.82% | |
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2132.00 | 45.50 | 2.18% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1471.00 | -15.65 | -1.05% |
Taiko Pharmaceutical Co., Ltd. Corporate Events
Taiko Pharmaceutical to Shift Listing From TSE Prime to Standard Market
Taiko Pharmaceutical Co., Ltd., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange under code 4574, is repositioning its stock market listing in line with its current scale and growth stage. The drugmaker emphasizes that its core po...
Taiko Pharmaceutical Seeks Shift From TSE Prime to Standard Market
Taiko Pharmaceutical Co., Ltd. has decided to seek a transfer from the Tokyo Stock Exchange Prime Market to the Standard Market after repeated challenges meeting the Prime’s tradable share market capitalization requirement. The move follows prior imp...
Taiko Pharmaceutical Announces FY2026 First-Half Results and Outlook
Taiko Pharmaceutical Co., Ltd. has released its consolidated financial results for the second quarter of the fiscal year ending December 31, 2026, covering the first half of FY2026. The disclosure outlines overall performance, including segment-level...
Taiko Pharmaceutical lifts sales but profits drop sharply in H1 2026
Taiko Pharmaceutical reported consolidated net sales of ¥2.64 billion for the first half of 2026, a 9.3% year-on-year increase, while operating profit fell 63.4% to ¥17 million and profit attributable to owners of parent plunged 84.1% to ¥44 million....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026